Skip to main content
. 2020 Feb 13;12:115–122. doi: 10.2147/CEOR.S220726

Table 3.

Results of the Baseline Case Evaluation of Liquid Biopsy Testing in Anti-HER2 Therapy in Advance Breast Cancer

Baseline Case Metastatic Her2-Positive Breast Cancer
Strategy Cost Incremental Cost Effectiveness (QALY) Incremental Effectiveness (QALY)
Liquid biopsy US $185,318.52
(555,955,586.746 COP)
US $7,333.17
(21,999,534.710 COP)
0.533466647 0.00042256
No liquid biopsy US $177,985.35 (533,956,052.037 COP) 0.533889206

Abbreviation: COP, Colombian Pesos.